Latest news in cancer
Gene Therapy for Gaucher’s Disease in China
Gene therapy for Gaucher’s disease in China offers a potential cure by correcting the faulty GBA gene. Using viral vectors or CRISPR, this treatment could...
Gene Therapy for Wilson’s Disease in China
Gene therapy for Wilson’s disease in China offers a groundbreaking cure by correcting the faulty ATP7B gene. With advanced viral vector and CRISPR-based...
Gene Therapy for Phenylketonuria in China
Gene therapy for phenylketonuria (PKU) in China represents a groundbreaking advancement in treating this rare genetic disorder. By delivering a functional PAH...
Best Cancer Hospitals in China 2025
Best Cancer Hospitals in China China has become a world leader in medical innovation, especially in oncology. The nation has, over the past decade, made...
Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor...
Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The...
Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
The FDA has approved mirdametinib for adult and pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The...
Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
The FDA approved the **treosulfan and fludarabine** preparative regimen for **allogeneic hematopoietic stem cell transplantation (alloHSCT)** in adult and...
Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
On January 27, 2025, the Food and Drug Administration sanctioned fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or...
Datopotamab deruxtecan-dlnk is approved by the USFDA for unresectable or metastatic, HR-positive, HER2-negative breast cancer
The FDA has approved datopotamab deruxtecan (Dato-DXd) to treat unresectable or metastatic HR-positive, HER2-negative breast cancer following previous...
Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer
The FDA has also approved the combination of sotorasib and panitumumab to treat KRAS G12C-mutated colorectal cancer that advanced on previous treatments. This...
Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma
The FDA has approved the combination of acalabrutinib, bendamustine, and rituximab for previously untreated mantle cell lymphoma (MCL). This regimen provides a...
Encorafenib with cetuximab and mFOLFOX6 is approved by the USFDA for metastatic colorectal cancer with a BRAF V600E mutation
The FDA has granted accelerated approval for the combination of encorafenib, cetuximab, and mFOLFOX6 for treating metastatic colorectal cancer (mCRC) with a...
Remestemcel-L-rknd is approved by the USFDA for steroid-refractory acute graft versus host disease in pediatric patients
The FDA has approved Remestemcel-L (Ryoncil, remestemcel-L-rknd) in pediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The...
Comparing Deceased Donor vs. Living Donor Liver Transplants: Pros and Cons
Liver transplant Liver transplant is a lifesaving surgery for patients with end-stage liver disease, acute liver failure, or some genetic liver...
Nutritional Advice for Liver Transplant Patients: Pre-and Post-Surgery
Liver transplantation is a sophisticated procedure, and nutrition plays an important role both in pre-transplant preparation and post-transplant recovery....
Immunotherapy for bladder cancer
Immunotherapy is revolutionizing bladder cancer treatment by harnessing the immune system to fight cancer cells. Checkpoint inhibitors like pembrolizumab and...
The Psychological Impact of Liver Transplantation on Patients and Families
Liver transplantation is a lifesaving operation, but it comes with huge psychological burdens on patients and their loved ones. From pre-transplant worry to...
Advances in Liver Transplant Surgery: Techniques and Technologies
Liver transplant surgery has come a long way with advances in minimally invasive procedures, organ preservation, and artificial intelligence. Advances in...
Liver Transplantation for Alcohol-Related Cirrhosis: Eligibility and Outcomes
Liver transplant is a critical treatment for cirrhosis due to alcoholism, providing an opportunity for recuperation for end-stage liver disease patients....
The Role of Living Donor Liver Transplants in Addressing Organ Shortages
Living donor liver transplant (LDLT) is vital in the treatment of organ deficits, with improved success rates and shorter waiting periods. With increased cases...
Understanding Post-Liver Transplant Medications: A Comprehensive Guide
Following a liver transplant, it is important to take lifelong medicines to avoid organ rejection and control resultant conditions. This manual deals with...
Ensartinib is approved by the USFDA for ALK-positive locally advanced or metastatic non-small cell lung cancer
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic...
Cosibelimab-ipdl is approved by the USFDA for metastatic or locally advanced cutaneous squamous cell carcinoma
The FDA has approved cosibelimab (iPDL1) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC). This PD-L1 inhibitor demonstrated...
Durvalumab is approved by the USFDA for limited-stage small cell lung cancer
The FDA has approved durvalumab (Imfinzi) for limited-stage small cell lung cancer (LS-SCLC), marking a significant advancement in treatment. This approval is...
Unlocking the Potential of Astraeus asiaticus: A Natural Anticancer and Antioxidant Agent
Astraeus asiaticus, an edible wild mushroom, has shown remarkable anticancer and antioxidant potential. Researchers identified key bioactive compounds that...
Zenocutuzumab-zbco is approved by the USFDA for non-small cell lung cancer and pancreatic adenocarcinoma
The FDA has granted accelerated approval to Zenocutuzumab for non-small cell lung cancer and pancreatic cancer with NRG1 gene fusion. This bispecific antibody...
Zanidatamab-hrii is approved by the USFDA for previously treated unresectable or metastatic HER2-positive biliary tract cancer
The FDA has granted accelerated approval to Zanidatamab for previously treated, unresectable, or metastatic HER2-positive cancers. This bispecific antibody...
Revumenib is approved by the USFDA for relapsed or refractory acute leukemia with a KMT2A translocation
The FDA has approved Revumenib for relapsed or refractory acute leukemia with KMT2A translocation. This breakthrough treatment offers new hope for patients...
Enhancing Cancer Outcomes: The Critical Role of Early CAR T-Cell Therapy
CAR T-cell therapy is revolutionizing cancer treatment, offering a highly personalized approach to fighting hematologic malignancies. Early intervention with...
Obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically...
Asciminib is approved by the USFDA for newly diagnosed chronic myeloid leukemia
On October 29, 2024, the FDA granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed Philadelphia chromosome-positive chronic...
Zolbetuximab-clzb with chemotherapy is approved by the USFDA for gastric or gastroesophageal junction adenocarcinoma
On October 18, 2024, the FDA approved zolbetuximab-clzb (Vyloy) combined with fluoropyrimidine- and platinum-based chemotherapy for first-line treatment of...
Inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi) combined with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated,...
Neoadjuvant/adjuvant nivolumab is approved by the USFDA for resectable non-small cell lung cancer
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet...
Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation
On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo) for treating advanced or metastatic medullary thyroid cancer (MTC) with...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.